PT-141 / Bremelanotide

Bremelanotide is a cyclic melanocortin receptor agonist investigated in sexual-function and central melanocortin signaling research.

Acts primarily through central melanocortin receptors rather than direct vascular smooth-muscle mechanisms.

Substantial human evidence and an FDA-approved prescription product for a specific indication.

Level I, Established human evidence

Approved-product evidence cannot establish the quality or equivalence of an independently manufactured research material.

Approved labeling includes nausea, flushing, headache, transient blood-pressure increases, and focal hyperpigmentation.

The active ingredient is used in an FDA-approved prescription drug; a research material is not an approved drug product.

Supplied strictly for in-vitro and ex-vivo laboratory research. Not for human or veterinary administration, diagnostic, or therapeutic use. Import and regulatory compliance remain the responsibility of the receiving researcher.

Every Cendrix lot ships with an HPLC purity chromatogram, mass-spectrometry identity confirmation, appearance and reconstitution observations, and endotoxin testing where applicable. Lot certificates are retrievable from the Quality page using the lot number printed on the vial.

External searches link to PubMed, ClinicalTrials.gov, Google Scholar, and FDA records. Cendrix does not endorse interpretations published in third-party sources.